Theodoros Karampelas
Athens, ESYE31 11527, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.
Journal: Journal of medicinal chemistry
Published: February 13, 2025
Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the "Undruggable" MYC.
Journal: ACS pharmacology & translational science
Published: August 05, 2024
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter-Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: April 03, 2024
Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular Carcinoma.
Journal: Cardiovascular and interventional radiology
Published: October 01, 2023
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.
Journal: Journal of medicinal chemistry
Published: December 30, 2021
Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation.
Journal: Pharmaceutical research
Published: June 05, 2021
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC.
Journal: Cancers
Published: March 11, 2021
Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Journal: European journal of medicinal chemistry
Published: June 11, 2020
Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy.
Journal: European journal of medicinal chemistry
Published: March 29, 2019
Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile.
Journal: European journal of medicinal chemistry
Published: November 20, 2018
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 29, 2017
Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.
Journal: Molecular pharmaceutics
Published: January 19, 2017
Last Updated: 09/26/2026